Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated:
Patient Assistance Program
The Novo Nordisk Patient Assistance Program (PAP) is based on our commitment to people living with diabetes. The Novo Nordisk PAP provides medication at no cost to those who qualify. There is no registration charge or monthly fee for participating.
Click here for a list of Novo Nordisk products covered by the PAP.
Who can participate in the Patient Assistance Program?
To be eligible for this program, your patient must:
- Be a US citizen or legal resident
- Have a total household income that qualifies. Visit the NeedyMeds website, which lists the current Federal Poverty Level (FPL) guidelines
- Have Medicare or no insurance (Note: Patients with private or commercial insurance are not eligible for the PAP)
- Not be enrolled in or qualify for any other federal, state, or government program such as Medicaid, Medicare Low-Income Subsidy (LIS, or Extra Help Program), or Veterans Affairs (VA) Benefits
- If patients are eligible for Medicaid or Medicare LIS, they must submit a copy of their denial letter with their application.
For patients on Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg
For patients on Ozempic® pen
- Most Medicare Part D plans cover Ozempic®. Medicare beneficiaries with Part D coverage will no longer be eligible to receive Ozempic® through the Patient Assistance Program.
- Next Steps:
- Your patient also can spread prescription costs throughout the plan year by enrolling in the Medicare Prescription Payment Plan (M3P). More information is available here.
- Uninsured patients will still have access to Ozempic® through the Patient Assistance Program; however, their total household income must be at or below 200% of the federal poverty level.
- Resources:
- Visit NeedyMeds website which lists the current FPL guidelines for more information.
For Medicare patients on Novo Nordisk insulins
For Medicare patients on Novo Nordisk insulins
- Total household income must be at or below 400% of the federal poverty level.
- Medicare beneficiaries with a total household income below 150% of the federal poverty level must provide proof of denial for Part D Extra Help to qualify.
- Next Steps:
- For more information on how to apply for the Extra Help Program, please click here. If your patient will be a Medicare patient in 2026 and meets eligibility requirements, please start the application here.
- Novo Nordisk has other programs to help make insulin affordable. Explore options here.
- For more information on how to apply for the Extra Help Program, please click here. If your patient will be a Medicare patient in 2026 and meets eligibility requirements, please start the application here.
- Medicare resources
The resources below provide additional information about Medicare updates in 2026:
For uninsured patients on all products
For uninsured patients on all products
- Total household income must be at or below 200% of the federal poverty level for Ozempic®.
- For all other medications, total household income must be at or below 400% of the federal poverty level.
- Uninsured patients must provide proof of a Medicaid denial prior to enrollment in the PAP if the patient’s total household income meets their state federal poverty limit thresholds. For more information about your state’s Medicaid program, you can click here. You can also visit the NeedyMeds website which lists the current FPL guidelines for more information.
- Next Steps:
- For uninsured insulin patients, Novo Nordisk has other programs to help make insulin more affordable. Click here for insulin affordability options.
An important note about medication eligibility in 2026
Some medicines will no longer be a part of the Patient Assistance Program for 2026. Please click here to see a list of Novo Nordisk medicines that are still covered by the program.
Instructions for applying
Fill out the application online
The Spanish application is coming soon.
Note: If you are eligible for Medicaid or Medicare LIS, you must submit a copy of your denial letter with your application.
STEP 1: Health care provider (HCP) application portion
Click here to submit the HCP portion of your patient's application. You’ll need your patient's email address.
After submitting your patient's online application, please eRx script to Neovance™ Specialty Pharmacy (NPI 1780811125). If you’re unable to eRx or are having issues, please reach out to the pharmacy at 1‑800‑488‑5908.
STEP 2: Patient application portion
Please advise your patient that they will receive a secure link via email to access the portal to complete their portion of the application.
STEP 3: Additional documents
During application, your patient may be prompted to provide additional documentation, such as Proof of Income, Medicaid LIS Denial, or Government ID.
STEP 4: Approval and delivery
If your application is approved, patients should expect a call from Neovance™ Specialty Pharmacy at 1‑800‑488‑5908 to schedule delivery of your medicine to your home.
Product availability subject to change without notice.
Novo Nordisk reserves the right to modify or cancel this program at any time without notice.
Important reminders for Medicaid and Medicare enrollees
Reminders
Patients who are eligible for Medicaid or Medicare LIS must submit a copy of their denial letter with their application
Qualified Medicare patients will be enrolled in the program through December 31st of the calendar year
Questions? Call Novo Nordisk toll-free at 1‑866‑310‑7549.
How to renew your patient's prescription
How to renew your patient's prescription
If the application is approved, patients should expect a call from Neovance™ Specialty Pharmacy at 1‑800‑488‑5908 to schedule delivery of medicine to their home. Your patient will receive a phone and/or texta notification from Neovance™ Specialty Pharmacy to coordinate delivery of refill shipments.
Patients can renew each year for as long as they qualify. For uninsured patients, an approved application is valid for 12 months. For patients with Medicare Part D coverage, an approved application is valid for the benefit year only. Some restrictions may apply.
Novo Nordisk reserves the right to modify or cancel this program at any time without notice.
aBased on the patient’s preferred communication method and program outreach consent opt-in.
Frequently asked questions
Online enrollment and eligibility details
Faxed applications are no longer processed. All applications must be submitted through the online enrollment system. This ensures applications are received in a consistent and complete format.
The online application may be completed by a health care provider. It may also be completed with the patient present, offering flexibility while ensuring accuracy of the information submitted.
Online applications are generally completed in less time than faxed submissions, offering a more streamlined and efficient process for most users.
Most offices find that online enrollment reduces follow-up requests and rework, ultimately saving time compared to fax-based workflows.
Patients must be a US citizen or legal resident and must meet all other eligibility requirements.
No, we no longer require that Medicare Part D patients spend $1000 out-of-pocket to be eligible for the program.
Application process and approval
If an application is submitted with all supporting documentation and all required fields completed, it will be processed within 2 business days. Any missing or incomplete information may cause a delay.
If approved, patients will receive a letter in the mail. Also, if a patient opts in for automated phone notification or text message on the application, they will receive an automated message.
Uninsured patients are enrolled for 12 months. Medicare patients are enrolled for a calendar year.
Once a patient is approved, their medication will arrive at their home within 5 business days. Patients should expect a call from Neovance™ Specialty Pharmacy at 1‑800‑488‑5908 to arrange delivery.
Direct-to-patient shipment
Yes, patients should expect a call from Neovance™ Specialty Pharmacy at 1‑800‑488‑5908 to arrange delivery.
Unfortunately, we are currently not able to ship directly to a pharmacy.
Direct-to-patient shipping reduces administrative responsibilities for your office, removes the need to store or handle medication, and helps limit patient inquiries regarding shipment status.
No. Prescribing, renewals, and clinical oversight remain unchanged. This update affects only delivery logistics.
Patients receive direct notifications and tracking information, reducing the need for offices to manage delivery questions.
Although we do our best to provide timely access to most program medications, their availability and delivery are not guaranteed. For example, the medications we offer are not always available on hand for delivery 365 days of the year. We typically notify the prescriber when availability or delivery of medications may be impacted.
In certain instances, we reserve the right to adjust the quantity of medication prescribed to align with our program guidelines. For example, Medicare Part D patient enrollments expire at the conclusion of each calendar year. Therefore, approved applicants who are also enrolled with Medicare Part D may receive less than the full quantity of their prescribed medication. However, if you believe there was an error in the quantity shipped, please contact us at 1-866-310-7549.
Change of doctor or address
Please contact us at 1-866-310-7549 so we can update your records.
Please contact us at 1-866-310-7549 so we can provide additional direction.
All eligible prescribed medications will be refilled automatically once a patient has been fully qualified and deemed eligible for the program. Certain medications are excluded. Please view the full list of excluded products.
A new online enrollment will need to be completed by the new prescriber.
Program information
Medicare Part D
Individuals with Medicare Part D coverage may apply for next year’s PAP enrollment after October 15, 2026. Please ensure patients complete the latest version of the application available for download above.
Find helpful resources
Connect patients to low-cost insulin options
Learn about low-cost insulin options that may be more affordable, especially for those without insurance or with high-deductible health insurance plans.
Resources and education
Help patients find inspiration and motivation for staying active, eating healthy, and building up their knowledge with resources and education from NovoCare®.